Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $79,057.05 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 295 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $267.99, for a total value of $79,057.05. Following the sale, the insider directly owned 183,774 shares of the company’s stock, valued at $49,249,594.26. This represents a 0.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $236,539.17.
• On Monday, July 27th, John Fesko sold 782 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $203,703.18.
• On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $291,683.92.

Natera Price Performance

NTRA stock opened at $322.10 on Friday. Natera, Inc. has a 12 month low of $149.38 and a 12 month high of $323.01. The firm’s 50-day moving average is $254.03 and its 200 day moving average is $223.79. The company has a market capitalization of $46.13 billion, a PE ratio of -236.84 and a beta of 1.51.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.82%. The company’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.74) EPS. Sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Meeder Advisory Services Inc. purchased a new stake in shares of Natera during the second quarter valued at $384,000. Meeder Asset Management Inc. purchased a new stake in Natera during the 2nd quarter valued at about $6,626,000. Citizens Financial Group Inc. RI acquired a new position in shares of Natera in the second quarter valued at about $492,000. K.J. Harrison & Partners Inc acquired a new position in shares of Natera in the second quarter valued at about $5,117,000. Finally, Focused Alpha LLC purchased a new position in shares of Natera in the second quarter worth about $472,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research analyst reports. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Natera in a research report on Monday, July 6th. Wolfe Research assumed coverage on shares of Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective on the stock. Robert W. Baird set a $348.00 target price on Natera in a report on Friday. Citigroup boosted their price target on Natera from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Royal Bank Of Canada boosted their target price on shares of Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $299.65.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.